Disease Overview:Alzheimers Disease-Identifying and Commercializing Market - PowerPoint PPT Presentation

View by Category
About This Presentation

Disease Overview:Alzheimers Disease-Identifying and Commercializing Market


Big Market Research presents this report which covers and includes a brief introduction to AD, including symptoms, pathophysiology, and overview of pharmacotherapy and treatment algorithms,the changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline Read The Complete Report On : – PowerPoint PPT presentation

Number of Views:30


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Disease Overview:Alzheimers Disease-Identifying and Commercializing Market

Frontier Pharma Alzheimers Disease-Identifying
and Commercializing Market
Large and Innovative Pipeline The active
Alzheimers Disease (AD) pipeline is populated
with 583 products, with a highly diverse range of
molecular targets. GBI Research analysis revealed
a high degree of innovation in this indication,
with 46 of the pipeline being first-in-class
products, acting on over 40 first-in-class
molecular targets. In addition, the pipeline is
characterized by the strong presence of therapies
that target multiple components implicated in the
amyloid cascade, several molecular targets of
which are known to trigger familial AD. Given
that the currently approved therapies for AD are
limited to acetyl cholinesterase inhibitors and
glutamate receptor antagonists, the pipeline
offers a broad range of treatment options that
may possess disease-modifying properties.
However, evaluation of the Preclinical and
clinical evidence for their therapeutic potential
reveals that the novelty of the molecular target
is not sufficient to effectively reduce the rate
of AD progression in human patients.
Report Description
  • Disease-Modifying Therapies Show Promise in
    Early-Stage Development
  • Programs undergoing Preclinical development
    exhibit diverse disease-modifying mechanisms of
    action, and many represent strong alternatives to
    targets with a direct role in the amyloid and tau
    processes due to their roles in promoting
    neuronal survival and plasticity, a process
    critical to memory and cognition. Brain-Derived
    Neurotrophic Factor (BDNF) and Nerve Growth
    Factor (NGF) are considered promising targets in
    AD, primarily due to their potency in exhibiting
    significant neuroprotective effects in
    Preclinical studies. Members of the
    caspase-mediated apoptotic cascade also show
    therapeutic potential, as early investigations
    have revealed an ability to modulate molecular
    mechanisms underlying synaptic plasticity in
    animal models, which translates into amelioration
    of behavioral deficits. Thus, growing insights
    into disease-causing processes in AD are being
    translated into a growing population of
    innovative therapeutic targets, as reflected in
    the highly innovative pipeline.

Key Segment
  • The merits of novel molecular targets depend
    largely on the body of Preclinical evidence
    underpinning their relevance to AD pathology.
    Many endpoints in Preclinical investigations
    focus on amelioration of amyloid burden and tau
    pathology, as well as cognitive performance in
    animal model systems.
  • Based on these assessment criteria, it appears
    that programs targeting the amyloid cascade, tau
    pathology, and the promotion of neuronal survival
    and plasticity all demonstrate promising efficacy
    profiles. Other first-in-class targets that are
    less directly aligned to these three processes
    may not be able to confer disease-modifying
    properties and therefore lack clinical and
    commercial potential.
  • Read The Complete Report On http//www.bigmarket

Key Market
  • Active Deals Landscape with Numerous Investment
  • The AD deals landscape has been highly active
    over the past eight years, with 83 licensing
    agreements and 103 co-development deals. Overall,
    non-first-in-class programs tend to have lower
    valuations than first-in-class programs across
    all stages of drug development, which highlights
    their commercial attractiveness, even in
    early-stage development. Although first-in-class
    programs are associated with greater risk, they
    have more potential to revolutionize or improve
    therapeutic options, meaning that identifying
    promising first-in-class compounds early in
    development offers the greatest potential
    commercial benefit to pharmaceutical companies.
  • With 153 first-in-class products that are
    currently in development having not yet been
    involved in a licensing or co-development deal,
    there are numerous opportunities for in-licensing
    or co-development in this indication.

  • The report covers and includes
  • A brief introduction to AD, including symptoms,
    pathophysiology, and overview of pharmacotherapy
    and treatment algorithms
  • The changing molecular target landscape between
    market and pipeline and particular focal points
    of innovation in the pipeline
  • A comprehensive review of the pipeline for
    first-in-class therapies, analyzed on the basis
    of stage of development, molecule type and
    molecular target
  • Identification and assessment of first-in-class
    molecular targets with a particular focus on
    early-stage programs for which clinical utility
    has yet to be evaluated, as well as literature
    reviews of novel molecular targets
  • Assessment of the licensing and co-development
    deal landscape for AD therapies and benchmarking
    of deals involving first-in-class versus

  • The report will assist business development and
    enable marketing executives to strategize their
    product launches, by allowing them to
  • Understand the focal shifts in molecular targets
    in the AD pipeline
  • Understand the distribution of pipeline programs
    by phase of development, molecule type and
    molecular target
  • Access a scientific and clinical analysis of
    first-in-class developmental programs for AD,
    benchmarked against non-first-in-class targets
  • Access a list of the first-in-class therapies
    potentially open to deal-making opportunities
  • To Get More Details Enquire _at_ http//www.bigmarket

Table Of Content
  • Executive Summary
  • The Case for Innovation
  • Clinical and Commercial Landscape
  • Clinical and Commercial Landscape
  • Assessment of Pipeline Product Innovation
  • Liver Cancer Patent Family Analysis
  • Signaling Network, Disease Causation and
    Innovation Alignment
  • First-in-Class Target Evaluation
  • Deals and Strategic Consolidations
  • Appendix
  • Read The Complete TOC _at_ http//www.bigmarketresear

Contact Us
Deep Joshi 5933 NE Win Sivers Drive, 205,
Portland, OR 97220 United States Direct 1
(617) 674-4143 Toll Free 1 (855) 711-1555 Fax
1 (855) 550-5975 Email help_at_bigmarketresearch
.com Web http//www.bigmarketresearch.com
About PowerShow.com